Brief: Bio-Rad Q2 Adjusted EPS USD 3.11 Vs. IBES Estimate USD 2.01
Aug 01 (Reuters) - Bio-Rad Q2 sales USD 638.5 million vs. IBES estimate USD 645.8 million. * Q2 net income USD -2,165.5 million * Q2 gross margin 55.6% * Q2 EBIT margin 15.9% * Q2 EPS USD -76.26
Recent news on Bio-Rad Laboratories
See all newsUS RESEARCH ROUNDUP-Cencora, Dave, Uber
Bio-Rad Laboratories, Inc. reports results for the quarter ended September 30 - Earnings Summary
Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth
Brief: Bio-Rad Q3 EBIT Margin -7.6%
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary